|Day's Range||77.02 - 78.36|
|52 Week Range||64.18 - 86.72|
|PE Ratio (TTM)||37.71|
|Dividend & Yield||2.08 (2.67%)|
|1y Target Est||N/A|
Novo Nordisk stock popped Tuesday after AstraZeneca said its Type 2 diabetes drug didn't reduce the risk of cardiovascular events in a trial.
Certain pharma stocks have significant upside potential.
A leading competitor's osteoporosis drug encountered serious side effects in a late stage trial.